, ,
Ashvattha Therapeutics

Nanomedicine Platform Takes Disease Targeting To The Next Level

About this Event

One of the major challenges with systemic treatments for inflammatory diseases is delivering therapeutics to the activated cells without impacting the healthy ones.

Ashvattha Therapeutics has solved this problem with a new precision nanomedicine platform technology based on hydroxyl dendrimers (HD). Drugs and imaging agents can be chemically linked to these non-toxic, metabolically stable molecules. HDs are smaller than antibodies and have properties that allow them to cross the blood-brain and blood-retinal barriers in regions of inflammation and be taken up by activated inflammatory cells.

Watch this webinar with Ashvattha CEO, Jeffrey Cleland, PhD. to hear how their nanomedicine platform is ready to take on a broad range of diseases including retinal disorders, neurodegenerative conditions and systemic inflammation. 

Hosted by Steven Saltzstein. CEO, Force Family Office

Video On Demand

– Recorded

March 14

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.